FDA approval of centanafadine marks a cautious advance in ADHD treatment options

The US FDA has approved centanafadine, marketed as Simtriyo, offering a new, potentially better-tolerated medication for ADHD patients, though questions remain about its comparative efficacy and place in therapy amidst existing treatments. The US Food and Drug Administration has approved…













